Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SURESH SUREDDI

Allopathic & Osteopathic Physicians Psychiatry & Neurology Psychiatry

NPI
1710932561
CMS profile
168162
Location
PLANO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$379,160.12

561 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Page 3 of 12; records 101–150 of 561 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SURESH SUREDDI

NPI 1710932561 · CMS profile ID 168162

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Psychiatry

PLANO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 12; records 101–150 of 561 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1710932561?year=2019&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SURESH SUREDDI, NPI 1710932561, CMS profile ID 168162. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 12; records 101–150 of 561 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1710932561?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). SURESH SUREDDI, NPI 1710932561, CMS profile ID 168162. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 12; records 101–150 of 561 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1710932561?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
SURESH SUREDDI, NPI 1710932561, CMS profile ID 168162, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 12; records 101–150 of 561 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1710932561?year=2019&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

561 matching records · $379,160.12 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 561 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 561.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Alkermes, Inc. $50.1410/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 686633495 CMS
Otsuka America Pharmaceutical, Inc. $116.6510/11/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 687491249 CMS
Otsuka America Pharmaceutical, Inc. $2,736.0010/11/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 687491251 CMS
Otsuka America Pharmaceutical, Inc. $116.6510/11/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 687491253 CMS
Alkermes, Inc. $1,600.0010/09/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 686633421 CMS
Alkermes, Inc. $2,700.0010/09/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 686633427 CMS
Otsuka America Pharmaceutical, Inc. $268.6910/09/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 687491241 CMS
Otsuka America Pharmaceutical, Inc. $15.4810/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 687491243 CMS
Otsuka America Pharmaceutical, Inc. $268.6810/09/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 687491245 CMS
Otsuka America Pharmaceutical, Inc. $95.9810/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 687491247 CMS
Allergan Inc. $720.8010/08/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671201357 CMS
Allergan Inc. $10.4610/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671201361 CMS
Allergan Inc. $90.6310/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671201363 CMS
Allergan Inc. $37.1210/08/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671201365 CMS
Allergan Inc. $4,375.0010/08/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671201369 CMS
Allergan Inc. $63.2810/08/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671201371 CMS
Allergan Inc. $14.8210/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671201375 CMS
Allergan Inc. $2,500.0010/08/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671201377 CMS
Neurocrine Biosciences, Inc. $80.0310/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693167215 CMS
Allergan Inc. $114.9110/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671201355 CMS
Otsuka America Pharmaceutical, Inc. $1.7510/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 687491239 CMS
Alkermes, Inc. $255.2009/30/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 686633383 CMS
Sunovion Pharmaceuticals Inc. $5.3209/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688007795 CMS
Neurocrine Biosciences, Inc. $14.8209/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693167213 CMS
Neurocrine Biosciences, Inc. $2,700.0009/27/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693167211 CMS
Alkermes, Inc. $13.5109/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 686633493 CMS
Alkermes, Inc. $1,450.0009/25/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 686633381 CMS
Alkermes, Inc. $353.9609/25/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 686633425 CMS
Alkermes, Inc. $118.6709/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 686633491 CMS
Otsuka America Pharmaceutical, Inc. $2,736.0009/24/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 687491235 CMS
Otsuka America Pharmaceutical, Inc. $2,304.0009/24/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 687491237 CMS
Alkermes, Inc. $2,050.0009/23/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 686633551 CMS
Otsuka America Pharmaceutical, Inc. $120.2709/21/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 687491231 CMS
Otsuka America Pharmaceutical, Inc. $120.2709/21/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 687491233 CMS
Teva Pharmaceuticals USA, Inc. $8.1809/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697731587 CMS
Otsuka America Pharmaceutical, Inc. $132.9809/19/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 687491223 CMS
Otsuka America Pharmaceutical, Inc. $13.9709/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 687491225 CMS
Otsuka America Pharmaceutical, Inc. $132.9809/19/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 687491227 CMS
Otsuka America Pharmaceutical, Inc. $119.7809/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 687491229 CMS
Alkermes, Inc. $234.1209/17/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 686633423 CMS
Alkermes, Inc. $43.0909/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 686633489 CMS
Alkermes, Inc. $117.4409/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 686633507 CMS
Neurocrine Biosciences, Inc. $2,400.0009/10/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693167205 CMS
Neurocrine Biosciences, Inc. $124.1209/10/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693167207 CMS
Neurocrine Biosciences, Inc. $110.0009/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693167209 CMS
Sunovion Pharmaceuticals Inc. $4.0909/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688007793 CMS
Teva Pharmaceuticals USA, Inc. $2.4009/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697811429 CMS
Teva Pharmaceuticals USA, Inc. $4.4509/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697811431 CMS
Allergan Inc. $19.7709/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671201345 CMS
Allergan Inc. $76.5609/04/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671201349 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $379,160.12 561
PY2020 $111,795.28 175
PY2021 $174,986.95 255
PY2022 $322,632.44 398
PY2023 $415,069.79 492
PY2024 $369,614.29 358
PY2025 $401,898.37 491

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,230,295.33 19
PY2024 Principal investigator $632,167.51 108
PY2023 Principal investigator $1,274,705.63 49
PY2022 Principal investigator $33,112.15 4
PY2021 Principal investigator $4,040.81 14
PY2020 Principal investigator $39,046.12 9
PY2019 Principal investigator $474,977.19 4

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

19 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $846,486.00 10/16/2025 Non-covered Recipient Entity
Insite Clinical Research
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder No dispute reported 06/30/2026 1235996611
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $54,159.00 10/06/2025 Non-covered Recipient Entity
Insite Clinical Research
A Phase 3, Open-label Extension Study to Assess the Long-term Safety of KarXT for the Treatment of Mania or Mania with Mixed Features in Bipolar-I Disorder No dispute reported 06/30/2026 1235996607
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $5,650.00 10/03/2025 Non-covered Recipient Entity
INSITE CLINICAL RESEARCH LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1244041341
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $23,250.00 09/12/2025 Non-covered Recipient Entity
INSITE CLINICAL RESEARCH LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1244041335
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $29,875.00 09/12/2025 Non-covered Recipient Entity
INSITE CLINICAL RESEARCH LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1244041337
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,250.00 09/12/2025 Non-covered Recipient Entity
INSITE CLINICAL RESEARCH LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1244041339
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $23,726.81 08/01/2025 Non-covered Recipient Entity
Insite Clinical Research
An open label, single arm, extension trial to examine long-term safety of BI 425809 once daily in patients with schizophrenia who have completed previous BI 425809 Phase III trials.(CONNEX-X) No dispute reported 06/30/2026 1220818759
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $171,618.58 07/30/2025 Non-covered Recipient Entity
INSITE CLINICAL RESEARCH LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1244041333
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,445.60 07/28/2025 Non-covered Recipient Entity
Insite Clinical Research
A Phase 3, Open-label Extension Study to Assess the Long-term Safety of KarXT for the Treatment of Mania or Mania with Mixed Features in Bipolar-I Disorder No dispute reported 06/30/2026 1235996609
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $14,550.00 07/22/2025 Non-covered Recipient Entity
INSITE CLINICAL RESEARCH LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1244041331
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $6,158.28 06/24/2025 Non-covered Recipient Entity
Insite Clinical Research
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder No dispute reported 06/30/2026 1235996605
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,060.00 06/19/2025 Non-covered Recipient Entity
INSITE CLINICAL RESEARCH LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1244041325
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $500.00 06/19/2025 Non-covered Recipient Entity
INSITE CLINICAL RESEARCH LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1244041327
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,278.00 06/19/2025 Non-covered Recipient Entity
INSITE CLINICAL RESEARCH LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1244041329
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $33,150.00 03/14/2025 Non-covered Recipient Entity
INSITE CLINICAL RESEARCH LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1244041323
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $30.80 02/20/2025 Non-covered Recipient Entity
INSITE CLINICAL RESEARCH LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1244041321
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $12,838.70 02/14/2025 Non-covered Recipient Entity
Insite Clinical Research
Connex 1 No dispute reported 06/30/2026 1220818757
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $30.80 01/07/2025 Non-covered Recipient Entity
INSITE CLINICAL RESEARCH LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1244041317
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,237.76 01/07/2025 Non-covered Recipient Entity
INSITE CLINICAL RESEARCH LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1244041319